)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
ADMA Biologics
ADMA Biologics (ADMA) investor relations material
ADMA Biologics Q3 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q3 2026 earnings summary4 Nov, 2026
Executive summary
Q3 revenue rose 5.1% YoY to $141.1M; ASCENIV growth and yield-enhanced production lifted gross margin to 70.8%, net income to $49.9M and Adjusted EBITDA to $77.3M.
FY26 revenue guidance was maintained at at least $530M, while minimum Adjusted EBITDA and Adjusted Net Income guidance increased to $275M and $180M, respectively.
Financial highlights
Q3 gross profit was $99.9M vs. $75.6M a year earlier; operating income was $67.8M vs. $51.0M.
Q3 GAAP net income was $49.9M vs. $36.4M; diluted EPS was $0.22 vs. $0.15. Adjusted net income was $51.1M and Adjusted basic EPS was $0.23.
9M revenue rose 2.4% to $380.0M; net income was $133.0M vs. $97.6M, and Adjusted EBITDA was $198.8M vs. $157.4M.
9M operating cash flow was $105.2M vs. $14.8M; cash and equivalents were $124.6M at September 30, 2026.
Outlook and guidance
FY26 revenue guidance remained at least $530M; minimum Adjusted EBITDA guidance increased to $275M from $265M and Adjusted Net Income to $180M from $170M.
Guidance assumes continued ASCENIV momentum and prudent standard IG market assumptions, without relying on a broad standard IG recovery; ASCENIV demand continued into Q4.
Management expected Q4 R&D spending near $10M, including additional plasma collections and conformance-lot manufacturing; 2027 R&D guidance was not provided.
SG-001 IND preparation is advancing following FDA feedback; firmer clinical and regulatory timelines are expected next year, and management is preparing for a potentially abbreviated registrational Phase III study.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from ADMA Biologics
- ASCENIV drove 24% revenue growth, margin expansion, and strong cash flow in Q2 2026.ADMA
Q2 2026 - Directors were elected, all proposals passed, and no shareholder questions were raised.ADMAAGM 2026
- ASCENIV growth and margin gains offset BIVIGAM declines amid IG market disruption.ADMAQ1 2026
- Votes will be cast on director elections, auditor ratification, and executive pay approval.ADMAProxy filing
- Virtual annual meeting to vote on directors, auditor, and executive pay, with Board support.ADMAProxy filing
- 2025 revenue up 20% to $510M, with 2026 guidance above $635M and strong margin growth.ADMAQ4 2025
- Q1 2025 revenue up 40%, margins rise, FDA yield process approved, $500M buyback launched.ADMAQ1 2025
- New plasma supply deals and yield enhancements position the company for rapid, high-margin growth.ADMA43rd Annual J.P. Morgan Healthcare Conference 2025
- 2024 revenue up 65% to $426.5M, with record Asceniv demand and raised future guidance.ADMAQ4 2024
Next ADMA Biologics earnings date
Q4 202625 Feb, 2027
ADMA Biologics
Next ADMA Biologics earnings date
Q4 202625 Feb, 2027
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
ADMA Biologics Inc. is a biopharmaceutical company specializing in the development, manufacturing, and commercialization of plasma-derived products. The company focuses on producing and marketing therapies for patients with immune deficiencies and other immune-compromised conditions. ADMA Biologics' product portfolio includes immunoglobulin therapies that help prevent infections in individuals with weakened immune systems. In addition to developing its own products, the company operates plasma collection centers to support its manufacturing needs and ensure a stable supply of raw materials. The company is headquartered in Ramsey, New Jersey, and its shares are listed on the Nasdaq Stock Market.